Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis

Item
http://www.wikidata.org/entity/Q33983611
Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosisEvaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Ciprofloxacin dosage and emergence of resistance in human commensal bacteriaNon-cystic fibrosis bronchiectasis.Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary diseaseDosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulationNeed for susceptibility testing guidelines for fastidious or less-frequently isolated bacteria.High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis.Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaRapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosisPharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients.New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria.
P2860

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis

Item
http://www.wikidata.org/entity/Q33983611
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Population pharmacokinetics an ...... patients with cystic fibrosis
@ast
Population pharmacokinetics an ...... patients with cystic fibrosis
@en
type
label
Population pharmacokinetics an ...... patients with cystic fibrosis
@ast
Population pharmacokinetics an ...... patients with cystic fibrosis
@en
prefLabel
Population pharmacokinetics an ...... patients with cystic fibrosis
@ast
Population pharmacokinetics an ...... patients with cystic fibrosis
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Population pharmacokinetics an ...... patients with cystic fibrosis
@en
P2093
P2860
P304
P31
P356
10.1128/AAC.45.12.3468-3473.2001
P407
P433
P478
P577
P5875
P698
P921
P932